You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奧賽康(002755.SZ)在2025年歐洲肺癌大會公佈創新藥利厄替尼用於非小細胞肺癌治療長期隨訪數據
格隆匯 03-26 18:26

格隆匯3月26日丨奧賽康(002755.SZ)公佈,公司的全資子公司江蘇奧賽康藥業有限公司於2025年3月26日至29日在2025年歐洲肺癌大會(ELCC)上以壁報形式,公佈創新藥利厄替尼用於EGFRT790M突變陽性局部晚期或轉移性非小細胞肺癌(NSCLC)治療的長期隨訪數據。

利厄替尼是一種新型的第三代EGFR酪氨酸激酶抑制劑(TKI),已完成EGFRT790M突變陽性NSCLC關鍵IIB期臨牀研究,對於既往EGFR-TKI治療後進展的EGFRT790M突變陽性局部晚期或轉移性NSCLC受試者已顯示出明顯的抗腫瘤療效。本次ELCC會議報道了該項IIB期研究的長期隨訪數據以及針對亞組患者的分析。利厄替尼在第一代或第二代EGFRTKI治療後病情進展的非小細胞肺癌患者長期隨訪中表現出持久的療效及長期生存獲益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account